STAT6 deficiency ameliorates severity of oxazolone colitis by decreasing expression of Claudin-2 and Th2-inducing cytokines

Journal of Immunology

Volumn 190, Issue 4, 2013, Pages 1849-1858

  Rosen, Michael J ^a   Chaturvedi, Rupesh ^a,b   Washington, M Kay ^a   Kuhnhein, Lindsay A ^a   Moore, Preston D ^a   Coggeshall, Scott S ^a   McDonough, Elizabeth M ^a   Weitkamp, Jörn Hendrik ^a   Singh, Amar B ^a   Coburn, Lori A ^a,b   Williams, Christopher S ^a,b   Yan, Fang ^a   Van Kaer, Luc ^a   Peebles , R Stokes ^a   Wilson, Keith T ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 2; INTERLEUKIN 13; INTERLEUKIN 33; OXAZOLONE; SHORT HAIRPIN RNA; STAT6 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; ELECTRIC RESISTANCE; EPITHELIUM CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MACROPHAGE; MALE; MOLECULAR PATHOLOGY; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; T LYMPHOCYTE; TH2 CELL; TIGHT JUNCTION; TRANSEPITHELIAL RESISTANCE; ULCERATIVE COLITIS; WILD TYPE;

EID: 84873537478     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201373     Document Type: Article

References (54)

1. Khor, B., A. Gardet, and R. J. Xavier. 2011. Genetics and pathogenesis of inflammatory bowel disease. Nature 474: 307-317.
2. Rutgeerts, P., W. J. Sandborn, B. G. Feagan, W. Reinisch, A. Olson, J. Johanns, S. Travers, D. Rachmilewitz, S. B. Hanauer, G. R. Lichtenstein, et al. 2005. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353: 2462-2476.
3. Allison, J., L. J. Herrinton, L. Liu, J. Yu, and J. Lowder. 2008. Natural history of severe ulcerative colitis in a community-based health plan. Clin. Gastroenterol. Hepatol. 6: 999-1003.
4. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157: 1261-1270.
5. Fuss, I. J., F. Heller, M. Boirivant, F. Leon, M. Yoshida, S. Fichtner-Feigl, Z. Yang, M. Exley, A. Kitani, R. S. Blumberg, et al. 2004. Nonclassical CD1drestricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest. 113: 1490-1497.
6. Heller, F., P. Florian, C. Bojarski, J. Richter, M. Christ, B. Hillenbrand, J. Mankertz, A. H. Gitter, N. Bürgel, M. Fromm, et al. 2005. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129: 550-564.
7. Hershey, G. K. 2003. IL-13 receptors and signaling pathways: an evolving web. J. Allergy Clin. Immunol. 111: 677-690, quiz 691.
8. Rosen, M. J., M. R. Frey, M. K. Washington, R. Chaturvedi, L. A. Kuhnhein, P. Matta, F. L. Revetta, K. T. Wilson, and D. B. Polk. 2011. STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunction. Inflamm. Bowel Dis. 17: 2224-2234.
9. Boirivant, M., I. J. Fuss, A. Chu, and W. Strober. 1998. Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J. Exp. Med. 188: 1929-1939.
10. Heller, F., I. J. Fuss, E. E. Nieuwenhuis, R. S. Blumberg, and W. Strober. 2002. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 17: 629-638.
11. Hoving, J. C., F. Kirstein, N. E. Nieuwenhuizen, L. C. Fick, E. Hobeika, M. Reth, and F. Brombacher. 2012. B cells that produce immunoglobulin E mediate colitis in BALB/c mice. Gastroenterology 142: 96-108.
12. Wirtz, S., C. Neufert, B. Weigmann, and M. F. Neurath. 2007. Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2: 541-546.
13. Edelblum, K. L., M. K. Washington, T. Koyama, S. Robine, M. Baccarini, and D. B. Polk. 2008. Raf protects against colitis by promoting mouse colon epithelial cell survival through NF-kappaB. Gastroenterology 135: 539-551.
14. Stanic, A. K., A. D. De Silva, J. J. Park, V. Sriram, S. Ichikawa, Y. Hirabyashi, K. Hayakawa, L. Van Kaer, R. R. Brutkiewicz, and S. Joyce. 2003. Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by beta-D-glucosylceramide synthase deficiency. Proc. Natl. Acad. Sci. USA 100: 1849-1854.
15. Becker, C., M. C. Fantini, and M. F. Neurath. 2006. High resolution colonoscopy in live mice. Nat. Protoc. 1: 2900-2904.
16. Kennedy, R. J., M. Hoper, K. Deodhar, P. J. Erwin, S. J. Kirk, and K. R. Gardiner. 2000. Interleukin 10-deficient colitis: new similarities to human inflammatory bowel disease. Br. J. Surg. 87: 1346-1351.
17. Scheiffele, F., and I. J. Fuss. 2002. Induction of TNBS colitis in mice. Curr. Protoc. Immunol. Chapter 15: Unit 15.19.
18. Takeda, K., M. Kamanaka, T. Tanaka, T. Kishimoto, and S. Akira. 1996. Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice. J. Immunol. 157: 3220-3222.
19. Pillemer, B. B., Z. Qi, B. Melgert, T. B. Oriss, P. Ray, and A. Ray. 2009. STAT6 activation confers upon T helper cells resistance to suppression by regulatory T cells. J. Immunol. 183: 155-163.
20. Takaki, H., K. Ichiyama, K. Koga, T. Chinen, G. Takaesu, Y. Sugiyama, S. Kato, A. Yoshimura, and T. Kobayashi. 2008. STAT6 Inhibits TGF-beta1-mediated Foxp3 induction through direct binding to the Foxp3 promoter, which is reverted by retinoic acid receptor. J. Biol. Chem. 283: 14955-14962.
21. Kaplan, M. H., U. Schindler, S. T. Smiley, and M. J. Grusby. 1996. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 4: 313-319.
22. Weber, C. R., D. R. Raleigh, L. Su, L. Shen, E. A. Sullivan, Y. Wang, and J. R. Turner. 2010. Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity. J. Biol. Chem. 285: 12037-12046.
23. Paul, W. E., and J. Zhu. 2010. How are T(H)2-type immune responses initiated and amplified? Nat. Rev. Immunol. 10: 225-235.
24. Beltrán, C. J., L. E. Núñez, D. Díaz- Jiménez, N. Farfan, E. Candia, C. Heine, F. López, M. J. González, R. Quera, and M. A. Hermoso. 2010. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 16: 1097-1107.
25. Pastorelli, L., R. R. Garg, S. B. Hoang, L. Spina, B. Mattioli, M. Scarpa, C. Fiocchi, M. Vecchi, and T. T. Pizarro. 2010. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc. Natl. Acad. Sci. USA 107: 8017-8022.
26. Seidelin, J. B., J. T. Bjerrum, M. Coskun, B. Widjaya, B. Vainer, and O. H. Nielsen. 2010. IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol. Lett. 128: 80-85.
27. Kobori, A., Y. Yagi, H. Imaeda, H. Ban, S. Bamba, T. Tsujikawa, Y. Saito, Y. Fujiyama, and A. Andoh. 2010. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J. Gastroenterol. 45: 999-1007.
28. Elrod, J. W., F. S. Laroux, J. Houghton, A. Carpenter, T. Ando, M. H. Jennings, M. Grisham, N. Walker, and J. S. Alexander. 2005. DSS-induced colitis is exacerbated in STAT-6 knockout mice. Inflamm. Bowel Dis. 11: 883-889.
29. Alex, P., N. C. Zachos, T. Nguyen, L. Gonzales, T. E. Chen, L. S. Conklin, M. Centola, and X. Li. 2009. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm. Bowel Dis. 15: 341-352.
30. Dieleman, L.A., M. J. Palmen, H. Akol, E. Bloemena, A. S. Peña, S. G. Meuwissen, and E. P. Van Rees. 1998. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin. Exp. Immunol. 114: 385-391.
31. Dieleman, L. A., B. U. Ridwan, G. S. Tennyson, K. W. Beagley, R. P. Bucy, and C. O. Elson. 1994. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107: 1643-1652.
32. + betabetaT cells. Am. J. Pathol. 162: 263-271.
33. Weng, M., D. Huntley, I.-F. Huang, O. Foye-Jackson, L. Wang, A. Sarkissian, Q. Zhou, W. A. Walker, B. J. Cherayil, and H. N. Shi. 2007. Alternatively activated macrophages in intestinal helminth infection: effects on concurrent bacterial colitis. J. Immunol. 179: 4721-4731.
34. Schmitz, H., C. Barmeyer, M. Fromm, N. Runkel, H. D. Foss, C. J. Bentzel, E. O. Riecken, and J. D. Schulzke. 1999. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology 116: 301-309.
35. Sanders, S. E., J. L. Madara, D. K. McGuirk, D. S. Gelman, and S. P. Colgan. 1995. Assessment of inflammatory events in epithelial permeability: a rapid screening method using fluorescein dextrans. Epithelial Cell Biol. 4: 25-34.
36. Prasad, S., R. Mingrino, K. Kaukinen, K. L. Hayes, R. M. Powell, T. T.MacDonald, and J. E. Collins. 2005. Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab. Invest. 85: 1139-1162.
37. Wu, D., R. Ahrens, H. Osterfeld, T. K. Noah, K. Groschwitz, P. S. Foster, K. A. Steinbrecher, M. E. Rothenberg, N. F. Shroyer, K. I. Matthaei, et al. 2011. Interleukin-13 (IL-13)/IL-13 receptor alpha1 (IL-13Ralpha1) signaling regulates intestinal epithelial cystic fibrosis transmembrane conductance regulator channel-dependent Cl-secretion. J. Biol. Chem. 286: 13357-13369.
38. Madden, K. B., L. Whitman, C. Sullivan, W. C. Gause, J. F. Urban, Jr., I. M. Katona, F. D. Finkelman, and T. Shea-Donohue. 2002. Role of STAT6 and mast cells in IL-4- and IL-13-induced alterations in murine intestinal epithelial cell function. J. Immunol. 169: 4417-4422.
39. Ceponis, P. J., F. Botelho, C. D. Richards, and D. M. McKay. 2000. Interleukins 4 and 13 increase intestinal epithelial permeability by a phosphatidylinositol 3-kinase pathway. Lack of evidence for STAT 6 involvement. J. Biol. Chem. 275: 29132-29137.
40. Iijima, H., M. F. Neurath, T. Nagaishi, J. N. Glickman, E. E. Nieuwenhuis, A. Nakajima, D. Chen, I. J. Fuss, N. Utku, D. N. Lewicki, et al. 2004. Specific regulation of T helper cell 1-mediated murine colitis by CEACAM1. J. Exp. Med. 199: 471-482.
41. Kurata, H., H. J. Lee, A. O'Garra, and N. Arai. 1999. Ectopic expression of activated Stat6 induces the expression of Th2-specific cytokines and transcription factors in developing Th1 cells. Immunity 11: 677-688.
42. Finkelman, F. D., S. C. Morris, T. Orekhova, M. Mori, D. Donaldson, S. L. Reiner, N. L. Reilly, L. Schopf, and J. F. Urban, Jr. 2000. Stat6 regulation of in vivo IL-4 responses. J. Immunol. 164: 2303-2310.
43. + lymphocytes with a Th2 cytokine profile. J. Immunol. 164: 3047-3055.
44. Ouyang, W., M. Löhning, Z. Gao, M. Assenmacher, S. Ranganath, A. Radbruch, and K. M. Murphy. 2000. Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment. Immunity 12: 27-37.
45. Zhu, J., B. Min, J. Hu-Li, C. J. Watson, A. Grinberg, Q. Wang, N. Killeen, J. F. Urban, Jr., L. Guo, and W. E. Paul. 2004. Conditional deletion of Gata3 shows its essential function in T(H)1-T(H)2 responses. Nat. Immunol. 5: 1157-1165.
46. Amsen, D., A. Antov, D. Jankovic, A. Sher, F. Radtke, A. Souabni, M. Busslinger, B. McCright, T. Gridley, and R. A. Flavell. 2007. Direct regulation of Gata3 expression determines the T helper differentiation potential of Notch. Immunity 27: 89-99.
47. Yu, Q., A. Sharma, S. Y. Oh, H.-G. Moon, M. Z. Hossain, T. M. Salay, K. E. Leeds, H. Du, B. Wu, M. L. Waterman, et al. 2009. T cell factor 1 initiates the T helper type 2 fate by inducing the transcription factor GATA-3 and repressing interferon-gamma. Nat. Immunol. 10: 992-999.
48. + T cells to generate a Th2-inducing cytokine environment. J. Exp. Med. 202: 793-804.
49. Rimoldi, M., M. Chieppa, V. Salucci, F. Avogadri, A. Sonzogni, G. M. Sampietro, A. Nespoli, G. Viale, P. Allavena, and M. Rescigno. 2005. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat. Immunol. 6: 507-514.
50. Taylor, B. C., C. Zaph, A. E. Troy, Y. Du, K. J. Guild, M. R. Comeau, and D. Artis. 2009. TSLP regulates intestinal immunity and inflammation in mouse models of helminth infection and colitis. J. Exp. Med. 206: 655-667.
51. Zeuthen, L. H., L. N. Fink, and H. Frokiaer. 2008. Epithelial cells prime the immune response to an array of gut-derived commensals towards a tolerogenic phenotype through distinct actions of thymic stromal lymphopoietin and transforming growth factor-beta. Immunology 123: 197-208.
52. Iliev, I. D., I. Spadoni, E. Mileti, G. Matteoli, A. Sonzogni, G. M. Sampietro, D. Foschi, F. Caprioli, G. Viale, and M. Rescigno. 2009. Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells. Gut 58: 1481-1489.
53. Schmitz, J., A. Owyang, E. Oldham, Y. Song, E. Murphy, T. K. McClanahan, G. Zurawski, M. Moshrefi, J. Qin, X. Li, et al. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-490.
54. Oboki, K., T. Ohno, N. Kajiwara, K. Arae, H. Morita, A. Ishii, A. Nambu, T. Abe, H. Kiyonari, K. Matsumoto, et al. 2010. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl. Acad. Sci. USA 107: 18581-18586.